Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations

Use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has proven effective therapy for advanced lung adenocarcinoma with mutant EGFR [1 –4]. The exon 21 p.L858R mutation and exon 19 deletions (19DEL) are the most common mutations and are sensitive to EGFR TKIs [5–7]. However, uncommon EGFR mutations have shown various responses to different EGFR TKIs [8–10]. An irreversible ErbB family blocker, afatinib, was found to be more e ffective against uncommon EGFR mutations than the first-generation TKIs gefitinib and erlotinib [8–10].

Source: Lung Cancer - May 16, 2019 Category: Cancer & Oncology Authors: Sheng-Kai Liang, Jen-Chung Ko, James Chih-Hsin Yang, Jin-Yuan Shih Source Type: research